Minimal immune response after transplantation of a cryopreserved human amniotic membrane on the ocular surface
Source abstract
Abstract
Introduction: Human amniotic membrane (hAM) is considered to have low immunogenicity since Akle et al. reported no anti-HLA antibodies (Abs) in four volunteers after subcutaneous grafting of fresh hAM in 1981. But the sensitivity of the detection methods has significantly improved since then. Furthermore, hAM graft is a massive local input of allogenic HLA-G whose potential immunogenicity has never been assessed. The objective of this study was to look for the presence of anti-HLA class I, II, and anti HLA-G Abs at 1 and 3 months after hAM transplantation on the ocular surface. Material and methods: Twenty-three patients who required a hAM graft on the ocular surface (cornea and/or conjunctiva) for any indication were enrolled in this prospective clinical study. Sera were collected on the day of transplantation and at 1- and 3-months post-transplantation (M0, M1, M3). Anti-HLA class I, and II Abs were assessed using the Luminex® Single Antigen technique. Anti HLA-G Abs were assessed using an in-house ELISA-based detection assay, derived from the Monoclonal Antibody specific Immobilization of Platelet Antigen (MAIPA) assay. Results: Ab apparition after transplantation. Six patients showed a significant increase of preformed Abs MFI (>50 %) during follow up although transient in one out of six. No anti-HLA-G Abs were identified before or after hAM transplantation. Conclusion: This is the first study to investigate anti-HLA class I, II, and anti HLA-G Abs in a clinical setting after cryopreserved hAM transplantation. The main finding of this study is the minimal humoral immune response in our patients, supporting the immunological safety of the procedure and the excellent clinical tolerance reported across various indications over decades of use.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Reproductive System and Pregnancy · Corneal Surgery and Treatments · Organ and Tissue Transplantation Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (61)
Show source-provided references
1. Perinatal derivatives: where do we stand? A roadmap of the human placenta and consensus for tissue and cell nomenclature10.3389/fbioe.2020.610544 ↗
2. Human amniotic membrane as a multifunctional biomaterial: recent advances and applications10.1177/08853282221137609 ↗
3. Applications of human amniotic membrane for tissue engineering10.3390/membranes11060387 ↗
4. Designing highly customizable human based platforms for cell culture using proteins from the amniotic membrane, biomater
5. Emerging strategies for the biofabrication of multilayer composite amniotic membranes for biomedical applications10.3390/ijms241914424 ↗
6. SKIN grafting at the johns hopkins hospital10.1097/00000658-190909000-00002 ↗
7. Plastic repair of conjunctival defects with fetal membranes10.1001/archopht.1940.00860130586006 ↗
8. Biological properties and surgical applications of the human amniotic membrane10.3389/fbioe.2022.1067480 ↗
9. Variations in amniotic membrane: relevance for clinical applications10.1136/bjo.2009.157941 ↗
10. The amniotic membrane in ophthalmology10.1016/j.survophthal.2003.10.004 ↗
11. Ophthalmic applications of preserved human amniotic membrane: a review of current indications10.1023/B:CATB.0000046067.25057.0a ↗
12. Impact of human amniotic membrane preparation on release of angiogenic factors10.1002/term.207 ↗
13. Angiogenic potential of cryopreserved amniotic membrane is enhanced through retention of all tissue components in their native State10.1089/wound.2015.0638 ↗
14. Amniotic membranes in ophthalmology: long term data on transplantation outcomes10.1007/s10561-015-9520-y ↗
15. Storage and qualification of viable intact human amniotic graft and technology transfer to a tissue bank10.1007/s10561-014-9437-x ↗
16. Questions about residual cell viability in cryopreserved human amniotic membrane and its impact on clinical applications10.3390/biomedicines10102456 ↗
17. Amniotic membrane in ophthalmology: properties, preparation, storage and indications for grafting-a review10.1007/s10561-017-9618-5 ↗
18. Perspectives on the use of decellularized/devitalized and lyophilized human perinatal tissues for bone repair: advantages and remaining challenges
19. Unlocking the regenerative properties of extraembryonic membrane-derived biomaterials in tissue engineering10.1016/j.actbio.2025.07.028 ↗
20. Recent advances in decellularized biomaterials for wound healing
21. Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine10.1186/s40824-023-00348-z ↗
22. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers10.1016/S0140-6736(81)91212-5 ↗
23. Expression of HLA antigens, beta 2-microglobulin and enzymes by human amniotic epithelial cells10.1038/295325a0 ↗
24. Immunogenicity of human amniotic membrane in experimental xenotransplantation
25. Summary of the 2023 (2022 data) annual reporting of serious adverse reactions and events for tissues and cells - European commission, (n.d.). https://health.ec.europa.eu/publications/summary-2023-2022-data-annual-reporting-serious-adverse-reactions-and-events-tissues-and-cells_en (accessed December 18, 2024).
26. Summary of the 2022 (2021 data) annual reporting of serious adverse reactions and events for tissues and cells - European commission, (n.d.). https://health.ec.europa.eu/publications/summary-2022-2021-data-annual-reporting-serious-adverse-reactions-and-events-tissues-and-cells_en (accessed May 23, 2025).
27. Amniotic membrane transplantation for ocular surface reconstruction10.1136/bjo.83.4.399 ↗
28. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency
29. New skin-equivalent model from de-epithelialized amnion membrane10.1007/s00441-006-0208-2 ↗
30. Amniotic membrane transplantation: a review of current indications in the management of ophthalmic disorders10.4103/0301-4738.33036 ↗
31. Reassessing the cryopreserved human amniotic membrane's low immunogenicity due to advances in histocompatibility
32. Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G10.1111/j.1600-0897.1997.tb00208.x ↗
33. Hypopyon after primary cryopreserved amniotic membrane transplantation for sterile corneal ulceration: a case report and review of the literature, case Rep
34. Hypopyon Iritis after primary fresh amniotic membrane transplantation10.1097/ICO.0b013e31814b8b94 ↗
35. Hypopyon after amniotic membrane transplantation10.1016/S0161-6420(01)00734-5 ↗
36. Hypopyon after repeated transplantation of human amniotic membrane onto the corneal surface10.1016/S0161-6420(00)00167-6 ↗
37. Evaluation of a new complement-dependent lymphocytotoxicity cross match method using an automated cell counter, the NucleoCounter® NC-3000TM10.1111/tan.15044 ↗
38. Characterization of the novel HLA-A∗33:246 allele using next-generation sequencing10.1111/tan.15194 ↗
39. Characterization of the novel HLA-B∗07:482 allele using next-generation sequencing methods10.1111/tan.15195 ↗
40. The novel allele identified using next-generation sequencing in a Melanesian individual10.1111/tan.15175 ↗
41. Characterization of 43 novel HLA-H alleles10.1111/tan.15203 ↗
42. Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patients10.1111/tan.15276 ↗
43. Strong humoral response after Covid-19 vaccination correlates with the common HLA allele A∗03:01 and protection from breakthrough infection10.1111/tan.15421 ↗
44. Validation of KIR3DL1 alleles assigned by next generation sequencing10.1111/tan.15613 ↗
45. A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: diagnostic and therapeutic management10.1111/trf.17093 ↗
46. Screening platelet function in blood donors10.1111/trf.16990 ↗
47. Characterisation of the novel HLA-A∗23:147 allele using new next-generation sequencing methods10.1111/tan.15766 ↗
48. Low prevalence of HLA-G antibodies in lung transplant patients detected using MAIPA-adapted protocol10.3390/ijms242216479 ↗
49. Sélection de produits transfusionnels pour limiter l’immunisation HLA avant allogreffe de cellules souches hématopoïétiques avec donneur mismatch (SFGM-TC)10.1016/j.bulcan.2025.03.016 ↗
50. Surgical application of human amniotic membrane and amnion-chorion membrane in the oral cavity and efficacy evaluation: corollary with ophthalmological and wound healing experiences10.3389/fbioe.2021.685128 ↗
51. “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males10.1097/TP.0b013e318186d87b ↗
52. Reassessment of T lymphocytes crossmatches results prediction with luminex class I single antigen flow beads assay10.1097/TP.0000000000001239 ↗
53. Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report, am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl
54. A new bead-based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay10.1111/trf.12509 ↗
55. Biological importance of human amniotic membrane in tissue engineering and regenerative medicine
56. HLA-G as a tolerogenic molecule in transplantation and pregnancy10.1155/2014/297073 ↗
57. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?10.1158/0008-5472.CAN-05-0097 ↗
58. The role of HLA-G in tumor escape: manipulating the phenotype and function of immune cells10.3389/fonc.2020.597468 ↗
59. Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: clinical relevance of HLA-F autoantibodies10.1111/cei.12724 ↗
60. Insights into HLA-G genetics provided by worldwide haplotype diversity10.3389/fimmu.2014.00476 ↗
61. Arnaiz-Villena · 2018 · vol. 5